A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2023-06-20
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-02 (study day 24); relationship: N
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-07 (study day 182); relationship: not assessed
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-06-21 (study day 348); relationship: not assessed
Data queries
No data queries.